ATE230986T1 - Verwendung von schilddrüsenhormone in ein medizinisches behandlungsverfahren - Google Patents

Verwendung von schilddrüsenhormone in ein medizinisches behandlungsverfahren

Info

Publication number
ATE230986T1
ATE230986T1 AT94921305T AT94921305T ATE230986T1 AT E230986 T1 ATE230986 T1 AT E230986T1 AT 94921305 T AT94921305 T AT 94921305T AT 94921305 T AT94921305 T AT 94921305T AT E230986 T1 ATE230986 T1 AT E230986T1
Authority
AT
Austria
Prior art keywords
medical treatment
treatment procedure
thyroid hormones
treatment
diiodothyronine
Prior art date
Application number
AT94921305T
Other languages
English (en)
Inventor
Gilbert H Mayor
Alecy Louis G D
Original Assignee
Univ Michigan
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, Knoll Ag filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE230986T1 publication Critical patent/ATE230986T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT94921305T 1993-06-22 1994-06-22 Verwendung von schilddrüsenhormone in ein medizinisches behandlungsverfahren ATE230986T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7980593A 1993-06-22 1993-06-22
PCT/US1994/006772 WO1995000135A1 (en) 1993-06-22 1994-06-22 Medical treatment using thyroid hormones

Publications (1)

Publication Number Publication Date
ATE230986T1 true ATE230986T1 (de) 2003-02-15

Family

ID=22152935

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94921305T ATE230986T1 (de) 1993-06-22 1994-06-22 Verwendung von schilddrüsenhormone in ein medizinisches behandlungsverfahren

Country Status (11)

Country Link
US (1) US5571840A (de)
EP (1) EP0751769B1 (de)
JP (1) JPH09503485A (de)
KR (1) KR100348117B1 (de)
AT (1) ATE230986T1 (de)
AU (1) AU680669B2 (de)
CA (1) CA2165822A1 (de)
DE (1) DE69432027T2 (de)
DK (1) DK0751769T3 (de)
ES (1) ES2192194T3 (de)
WO (1) WO1995000135A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401891D0 (en) 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US6702265B1 (en) 1999-02-10 2004-03-09 Erik Zapletal Balanced suspension system
WO2000064448A1 (en) 1999-04-27 2000-11-02 Board Of Regents, The University Of Texas System A composition and method for treatment of cerebral ischemia
AU778522B2 (en) 1999-10-29 2004-12-09 Orion Corporation Treatment or prevention of hypotension and shock
CA2429196A1 (en) * 2000-03-24 2001-10-04 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
WO2002066017A1 (en) * 2001-02-20 2002-08-29 Abbott Laboratories Liothyronine sodium and levothyroxine sodium combination
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20040156893A1 (en) * 2003-02-11 2004-08-12 Irwin Klein Method for treating hypothyroidism
ITRM20030363A1 (it) * 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US8071134B2 (en) 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
CA2539288C (en) * 2003-09-15 2015-05-12 Shaker A. Mousa Thyroid hormone analogs and methods of use
AU2004293013B2 (en) * 2003-11-19 2011-04-28 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
EP1793814B1 (de) * 2004-09-15 2015-01-21 NanoPharmaceuticals LLC Schilddrüsenhormon-analoga zur hemmung von angiogenese
US20060128797A1 (en) * 2004-12-15 2006-06-15 Yanming Wang Method and composition for resuscitation
AU2006230557A1 (en) * 2005-03-31 2006-10-05 King Pharmaceuticals Research & Development, Inc. Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
WO2006128056A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US20100209382A1 (en) 2005-09-16 2010-08-19 Ordway Research Institute, Inc. Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use
ES2535005T3 (es) 2006-12-22 2015-05-04 Nanopharmaceuticals Llc Formulaciones de nanopartículas y de polímeros para análogos, antagonistas y formulaciones de la hormona tiroidea, y usos de los mismos
US9180107B2 (en) 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
NZ596976A (en) * 2009-05-15 2014-05-30 Recro Pharma Inc Sublingual dexmedetomidine compositions and methods of use thereof
CA2765792C (en) 2009-06-17 2017-03-28 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
EP2787970B1 (de) 2011-12-11 2018-04-11 Recro Pharma, Inc. Intranasale dexmedetomidinzusammensetzungen und verfahren zur verwendung davon
US10060934B2 (en) 2013-11-18 2018-08-28 Nanopharmaceuticals Llc Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof
WO2017003125A1 (ko) * 2015-06-29 2017-01-05 한양대학교 산학협력단 트리요오드티로닌, 티록신 또는 이의 염을 포함하는 뇌신경계 질환의 예방, 개선 또는 치료용 조성물
JP7074749B2 (ja) 2016-06-07 2022-05-24 ナノファーマシューティカルズ エルエルシー αｖβ３インテグリン甲状腺アンタゴニストにコンジュゲートした非開裂性ポリマー
BR112019010249A2 (pt) 2016-11-21 2019-09-10 Viking Therapeutics Inc método de tratamento de doença de armazenamento de glicogênio
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
AU2018280236B2 (en) 2017-06-07 2024-06-06 Supira Medical, Inc. Intravascular fluid movement devices, systems, and methods of use
EP3710076B1 (de) 2017-11-13 2023-12-27 Shifamed Holdings, LLC Intravaskuläre fluidbewegungsvorrichtungen, systeme und verwendungsverfahren
EP4085965A1 (de) 2018-02-01 2022-11-09 Shifamed Holdings, LLC Intravaskuläre blutpumpen und verfahren zur verwendung und herstellung
KR20200138283A (ko) 2018-03-22 2020-12-09 바이킹 테라퓨틱스 인코포레이티드 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US12161857B2 (en) 2018-07-31 2024-12-10 Shifamed Holdings, Llc Intravascular blood pumps and methods of use
US12220570B2 (en) 2018-10-05 2025-02-11 Shifamed Holdings, Llc Intravascular blood pumps and methods of use
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
ES2942441T3 (es) * 2019-01-09 2023-06-01 Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A L-triyodotironina (T3) para el uso en la limitación de la obstrucción microvascular
WO2021011473A1 (en) 2019-07-12 2021-01-21 Shifamed Holdings, Llc Intravascular blood pumps and methods of manufacture and use
US11654275B2 (en) 2019-07-22 2023-05-23 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
EP4010046A4 (de) 2019-08-07 2023-08-30 Calomeni, Michael Katheterblutpumpen und zusammenklappbare pumpengehäuse
EP4501393A3 (de) 2019-09-25 2025-04-09 Shifamed Holdings, LLC Katheterblutpumpen und zusammenklappbare pumpengehäuse
EP4034184B1 (de) 2019-09-25 2026-03-18 Supira Medical, Inc. Katheterblutpumpen und kollabierbare blutleitungen
GR1010068B (el) * 2020-04-21 2021-09-01 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE" Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237435B (it) * 1989-12-14 1993-06-04 Farmaco attivo nel ripristino della plasticita' neuronale.
GB2240474B (en) * 1990-02-05 1994-01-12 British Tech Group Thyroid hormone cardiac treatment
US5158978A (en) * 1990-02-05 1992-10-27 British Technology Group (U.S.A.) Thyroid hormone treatment of acute cardiovascular compromise

Also Published As

Publication number Publication date
ES2192194T3 (es) 2003-10-01
AU7208094A (en) 1995-01-17
EP0751769B1 (de) 2003-01-15
WO1995000135A1 (en) 1995-01-05
DE69432027T2 (de) 2003-10-09
JPH09503485A (ja) 1997-04-08
CA2165822A1 (en) 1995-01-05
KR100348117B1 (ko) 2002-12-02
DE69432027D1 (de) 2003-02-20
US5571840A (en) 1996-11-05
EP0751769A4 (de) 1998-05-27
DK0751769T3 (da) 2003-04-07
AU680669B2 (en) 1997-08-07
EP0751769A1 (de) 1997-01-08

Similar Documents

Publication Publication Date Title
ATE230986T1 (de) Verwendung von schilddrüsenhormone in ein medizinisches behandlungsverfahren
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
DE3752112D1 (de) Verwendung von Inositoltriphosphat zur Behandlung von Entzündungen
ATE78169T1 (de) Behandlung von diabetes durch kombinierte insulinformen.
DK581685A (da) Transderimalt system for timolol-indgift
ATE180255T1 (de) Guanidinderivate mit therapeutischer wirkung
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
MY104006A (en) 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases.
DE58906387D1 (de) Verwendung von Benzimidazolen zur Herstellung eines Arzneimittels mit antiischämischen Wirkungen am Herzen und dessen Kombinationen mit Beta-Blockern oder Bradycardica.
ES472847A1 (es) Procedimiento para la preparacion de la 2-bromoergosina y sus sales acidas de adicion
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
BR9708388A (pt) Solução aquosa de hemoglobina polimerizada piridoxilada e processo de sua preparação.
MY104521A (en) Treatment of depression.
ES8704962A1 (es) Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida.
DE69600367D1 (de) Verwendung von Sulfasalazin und/oder dessen aktiven Metaboliten zur Herstellung eines Arzneimittels zur Behandlung von venöser Insuffizienz und venösen Ulcera
GB9106278D0 (en) Method of treatment
DE3275060D1 (en) Use of beta-(1-adamantyl)-alpha, alpha-dimethylethylamine for the manufacture of a medicament for the treatment of otitis externa in dogs
DE69627298D1 (de) Verwendung von sklareolide für die behandlung von excessiven zellwachstumskrankheiten
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
ATE87482T1 (de) Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.
ATE89726T1 (de) Erhoehung des ausfliessens waessriger koerperfluessigkeit.
ES8500055A1 (es) Procedimiento para la obtencion de un medicamento a base de un derivado de pirazolinona.
ATE40795T1 (de) Verwendung eines zerebral und peripher wirkenden antihypoxidotikums.
DE3685988D1 (de) Verwendung von "naftidrofuryl" zur behandlung von neuropathien.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0751769

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee